Tonix Pharma Shares FDA Response For COVID-19 Vaccine Candidate Human Study

Tonix Pharmaceuticals Holding Corp TNXP announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vaccine candidate.
Based on the response, the Company expects to begin a Phase 1 study in 1H of 2022.
TNX-1800 is a live modified horsepox virus vaccine designed to express the Spike protein of the SARS-CoV-2 virus and elicit a predominant T cell response.
Related Content: Tonix Pharma To Start Mid-Stage Long COVID Trial In Q4.
Price Action: TNXP shares are up 0.02% at $0.66 during the market session on the last check Monday.

Momentum74.95

GrowthNot Available

QualityNot Available

Value54.36

Short

Medium

Long